MedTrace Logo

Performance of the Tasman Continuous Positive Airway Pressure (CPAP) System

NCT01171066 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2021-02-04

No results posted yet for this study

Summary

Assessment of the performance of the Tasman CPAP system in treating obstructive sleep apnea. The purpose of this study is to (1) evaluate the performance of this system in the efficacy of the treatment in comparison to S8 Escape, and (2) to evaluate the performance of the Tasman device via subjective assessment of comfort and ease of breathing compared to the participant's current CPAP device.

Conditions

Interventions

DEVICE

Tasman CPAP system

Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.

Sponsors & Collaborators

  • ResMed

    lead INDUSTRY

Principal Investigators

  • Klaus Schindhelm · ResMed

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01171066 on ClinicalTrials.gov